Cat. No.: HY-189697

NSC 852426

NSC 852426 is a PDGFRα/VEGFR-2 inhibitor with IC₅₀ values of 1.179 μM and 1.818 μM, respectively. NSC 852426 inhibits AKT and ERK1/2 phosphorylation, upregulates P53, BAX, and caspase-3 while inhibiting Bcl-2, and induces intrinsic mitochondrial apoptosis. NSC 852426 exhibits selective antiproliferative and cytotoxic effects against multiple cancer cell lines, and shows moderate selectivity for leukemia and colon cancer subgroups. NSC 852426 can be used in cancer-related research, such as leukemia and colon cancer.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

화학식: C₂₂H₁₇N₃O₄
분자량:387.39

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (278 KB)

NSC 852426 Chemical Structure

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target

^[1]

VEGFR2

1.818 μM (IC₅₀)

PDGFRα

1.179 μM (IC₅₀)

Caspase 3

Bax

Bcl-2

All Bcl-2 Family Isoforms :

All PDGFR Isoforms :

All VEGFR Isoforms :

All Akt Isoforms :

All Caspase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	GI50	2.33 μM	Antiproliferative activity against human CCRF-CEM cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human CCRF-CEM cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
HL-60(TB)	GI50	3.67 μM	Antiproliferative activity against human HL-60(TB) cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human HL-60(TB) cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
K562	GI50	3.13 μM	Antiproliferative activity against human K-562 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human K-562 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
MOLT-4	GI50	2.07 μM	Antiproliferative activity against human MOLT-4 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human MOLT-4 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
RPMI-8226	GI50	0.69 μM	Antiproliferative activity against human RPMI-8226 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human RPMI-8226 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
SR	GI50	0.28 μM	Antiproliferative activity against human SR cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human SR cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
A549	GI50	10.4 μM	Antiproliferative activity against human A549/ATCC cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human A549/ATCC cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
EKVX	GI50	10.6 μM	Antiproliferative activity against human EKVX cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human EKVX cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
HOP-62	GI50	4.99 μM	Antiproliferative activity against human HOP-62 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human HOP-62 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
HOP-92	GI50	3.35 μM	Antiproliferative activity against human HOP-92 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human HOP-92 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
NCI-H226	GI50	6.62 μM	Antiproliferative activity against human NCI-H226 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human NCI-H226 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
NCI-H23	GI50	3.71 μM	Antiproliferative activity against human NCI-H23 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human NCI-H23 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
NCI-H322M	GI50	20.1 μM	Antiproliferative activity against human NCI-H322M cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human NCI-H322M cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
NCI-H460	GI50	6.81 μM	Antiproliferative activity against human NCI-H460 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human NCI-H460 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
NCI-H522	GI50	1.04 μM	Antiproliferative activity against human NCI-H522 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human NCI-H522 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
COLO 205	GI50	18.7 μM	Antiproliferative activity against human COLO205 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human COLO205 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
HCC 2998	GI50	2.04 μM	Antiproliferative activity against human HCC-2998 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human HCC-2998 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
HCT-116	GI50	1.66 μM	Antiproliferative activity against human HCT-116 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human HCT-116 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
HCT-15	GI50	3.74 μM	Antiproliferative activity against human HCT-15 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human HCT-15 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
HT-29	GI50	4.75 μM	Antiproliferative activity against human HT29 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human HT29 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
KM12	GI50	2.37 μM	Antiproliferative activity against human KM12 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human KM12 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
SW-620	GI50	4.31 μM	Antiproliferative activity against human SW-620 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human SW-620 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
SF-268	GI50	5.69 μM	Antiproliferative activity against human SF-268 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human SF-268 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
SF-295	GI50	7.49 μM	Antiproliferative activity against human SF-295 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human SF-295 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
SF-539	GI50	2.11 μM	Antiproliferative activity against human SF-539 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human SF-539 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
SNB-19	GI50	12.0 μM	Antiproliferative activity against human SNB-19 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human SNB-19 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
SNB-75	GI50	13.8 μM	Antiproliferative activity against human SNB-75 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human SNB-75 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
U-251	GI50	2.46 μM	Antiproliferative activity against human U251 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human U251 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
LOX IMVI	GI50	2.97 μM	Antiproliferative activity against human LOX IMVI cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human LOX IMVI cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
Malme-3M	GI50	17.3 μM	Antiproliferative activity against human MALME-3M cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human MALME-3M cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
M14	GI50	3.96 μM	Antiproliferative activity against human M14 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human M14 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
MDA-MB-435	GI50	5.17 μM	Antiproliferative activity against human MDA-MB-435 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human MDA-MB-435 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
SK-MEL-2	GI50	6.98 μM	Antiproliferative activity against human SK-MEL-2 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human SK-MEL-2 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
SK-MEL-28	GI50	13.9 μM	Antiproliferative activity against human SK-MEL-28 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human SK-MEL-28 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
SK-MEL-5	GI50	10.6 μM	Antiproliferative activity against human SK-MEL-5 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human SK-MEL-5 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
UACC-257	GI50	4.54 μM	Antiproliferative activity against human UACC-257 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human UACC-257 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
UACC-62	GI50	7.70 μM	Antiproliferative activity against human UACC-62 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human UACC-62 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
IGROV-1	GI50	6.20 μM	Antiproliferative activity against human IGROV1 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human IGROV1 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
OVCAR-3	GI50	7.07 μM	Antiproliferative activity against human OVCAR-3 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human OVCAR-3 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
OVCAR-4	GI50	8.57 μM	Antiproliferative activity against human OVCAR-4 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human OVCAR-4 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
OVCAR-5	GI50	24.6 μM	Antiproliferative activity against human OVCAR-5 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human OVCAR-5 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
OVCAR-8	GI50	5.90 μM	Antiproliferative activity against human OVCAR-8 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human OVCAR-8 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
SK-OV-3	GI50	2.41 μM	Antiproliferative activity against human SK-OV-3 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human SK-OV-3 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
786-0	GI50	3.77 μM	Antiproliferative activity against human 786-0 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human 786-0 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
A498	GI50	2.13 μM	Antiproliferative activity against human A498 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human A498 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
CAKI-1	GI50	8.17 μM	Antiproliferative activity against human CAKI-1 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human CAKI-1 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
RXF 393	GI50	2.46 μM	Antiproliferative activity against human RXF 393 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human RXF 393 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
SN12C	GI50	5.97 μM	Antiproliferative activity against human SN12C cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human SN12C cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
TK-10	GI50	9.55 μM	Antiproliferative activity against human TK-10 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human TK-10 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
UO-31	GI50	10.9 μM	Antiproliferative activity against human UO-31 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human UO-31 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
PC-3	GI50	8.93 μM	Antiproliferative activity against human PC-3 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human PC-3 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
DU-145	GI50	6.45 μM	Antiproliferative activity against human DU-145 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human DU-145 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
MCF7	GI50	2.13 μM	Antiproliferative activity against human MCF7 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human MCF7 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
MDA-MB-231	GI50	13.8 μM	Antiproliferative activity against human MDA-MB-231/ATCC cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human MDA-MB-231/ATCC cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
Hs-578T	GI50	2.59 μM	Antiproliferative activity against human HS 578T cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human HS 578T cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
BT-549	GI50	2.23 μM	Antiproliferative activity against human BT-549 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human BT-549 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
T47D	GI50	3.47 μM	Antiproliferative activity against human T-47D cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human T-47D cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
MDA-MB-468	GI50	2.33 μM	Antiproliferative activity against human MDA-MB-468 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay. Antiproliferative activity against human MDA-MB-468 cells assessed as 50% growth inhibition after 48 hrs by NCI five-dose assay.	42748748
WI-38	IC50	146.64 μM	Cytotoxicity against normal human lung fibroblast WI-38 cells assessed as 50% inhibitory concentration by MTT assay. Cytotoxicity against normal human lung fibroblast WI-38 cells assessed as 50% inhibitory concentration by MTT assay.	42748748
Vero	IC50	209.16 μM	Cytotoxicity against african green monkey kidney epithelial VERO cells assessed as 50% inhibitory concentration by MTT assay. Cytotoxicity against african green monkey kidney epithelial VERO cells assessed as 50% inhibitory concentration by MTT assay.	42748748

In Vitro

OthersAnti-cancerApoptosis

Others

NSC 852426 (compound 7) inhibits VEGFR-2 with an IC₅₀ of 1.818 μM and PDGFRa with an IC₅₀ of 1.179 μM in cell-free kinase assays^[1].

Anti-cancer

NSC 852426 (11 μM; 48 h) showed broad single-dose GI% activity across multiple NCI 60 cell lines, with the highest GI% values observed in leukemia cell lines (e.g., RPMI-8226 199.09%, SR 199.81%)^[1].
NSC 852426 (0.01-100 mM; 48 h) had a full-panel MG-MID GI₅₀ of 6.18 μM, with moderate selectivity for leukemia (SI 3.04) and colon cancer (SI 4.57), and GI₅₀ values of 0.28 μM in leukemia SR and 1.66 μM in colon HCT-116^[1].
NSC 852426 showed low cytotoxicity in normal WI-38 (IC₅₀ 146.64 μM) and VERO (IC₅₀ 209.16 μM) cells, with a wide safety window^[1].
NSC 852426 inhibited p-AKT to 0.286-fold of the control and p-ERK1/2 to 0.291-fold of the control in HCT-116 cells^[1].

Anti-cancer

Apoptosis

NSC 852426 (2.5 μg/mL) induced intrinsic mitochondrial apoptosis in HCT-116 cells, with P53 upregulated 5.9-fold, the BAX/Bcl-2 ratio increased 22-fold, and caspase-3 increased 2.3-fold^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

NCI 60 human tumor cell lines (leukemia, NSCLC, colon, CNS, melanoma, ovarian, renal, prostate, breast)
Concentration:

11 μM
Incubation Time:

48 h
Result:

Exhibited NCI‑60 one‑dose growth‑inhibition (GI%) profiles covering diverse human tumour sub‑panels.
Exhibited pronounced growth‑inhibitory potency against the majority of leukemia cell lines, including CCRF‑CEM, HL‑60(TB), MOLT‑4, RPMI‑8226 and SR.
Exhibited strong cytotoxic responses for partial colon, melanoma and ovarian cancer cell strains such as HCT‑116, LOX IMVI and SK‑OV‑3.
Exhibited heterogeneous antiproliferative outcomes across NSCLC, CNS, renal, prostate and breast cancer cell models, with cell‑line‑dependent high or low growth‑inhibition magnitudes.

Cell Cytotoxicity Assay^[1]

Cell Line:

NCI 60 human tumor cell lines (nine tumor subpanels)
Concentration:

0.01, 0.1, 1, 11, 100 mM
Incubation Time:

48 h
Result:

Displayed NCI‑60 five‑dose antiproliferative GI₅₀ (micromolar) data across nine human tumour sub‑panels.
Displayed outstanding potency against leukemia cell lines, with sub‑micromolar GI₅₀ values for RPMI‑8226 and SR, and leukemia sub‑panel MG‑MID value of 2.03 micromolar.
Displayed favourable overall activity against colon, breast and renal cancer sub‑panels, whose respective MG‑MID values reached 5.37, 4.43 and 5.37 micromolar.
Displayed relatively weaker average inhibitory potency for NSCLC, CNS, melanoma, ovarian and prostate cancer sub‑panels, with corresponding MG‑MID values ranging from 7.21 to 8.12 micromolar.
Displayed full‑panel MG‑MID GI₅₀ of 6.18 micromolar, and yielded selectivity indices of 3.04 for leukemia and 4.57 for colon cancer, while presenting low‑to‑moderate selectivity indices for other tumour sub‑panels.

Related Protocols :

Chemical Information

분자량 387.39
화학식 C₂₂H₁₇N₃O₄
SMILES

O=C(NC1=CC=CC=C1)NC2=CC=C(C(/C=C/C3=CC=C([N+]([O-])=O)C=C3)=O)C=C2
선적

Room temperature in continental US; may vary elsewhere.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ismail MMF, et al. Discovery of new 1-aryl-3-phenylureas as promising PDGFRa and VEGFR-2 inhibitors and apoptosis inducers. Bioorganic chemistry. 2026 Sep 10;182:110505.

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

NSC 852426

All Bcl-2 Family Isoforms

All PDGFR Isoforms

All VEGFR Isoforms

All Akt Isoforms

All Caspase Isoforms